肌少症与炎症性肠病死亡率增加相关:长期前瞻性队列研究
该前瞻性队列纳入4966例炎症性肠病患者(平均年龄56.9±8.0岁,51.6%女性),按欧洲老年人肌少症工作组2标准评估肌少症。中位随访14.6年, probable肌少症和确诊肌少症分别与全因死亡风险增加47%和140%相关。
要点
- 肌少症在炎症性肠病患者中与长期全因死亡风险增加独立相关。
- probable肌少症和确诊肌少症患者死亡风险分别增加47%和140%。
- 肌少症评估有助于老年炎症性肠病患者的预后风险分层。
核心结论
- probable肌少症和确诊肌少症均增加炎症性肠病患者长期全因死亡风险。
研究设计与样本
- 前瞻性队列研究,纳入4966例炎症性肠病患者,平均年龄56.9±8.0岁,51.6%女性。
- 肌少症依据欧洲老年人肌少症工作组2标准评估,主要结局为全因死亡,采用多变量Cox比例风险模型分析。
主要发现
- 中位随访14.6年,共564例(11.4%)全因死亡。
- probable肌少症775例(14.6%),其中死亡136例(17.5%);确诊肌少症34例(0.7%),其中死亡10例(29.4%)。
- 与无肌少症相比,probable肌少症死亡风险增加47%(HR=1.47,95%CI:1.20-1.80,P<0.001)。
- 与无肌少症相比,确诊肌少症死亡风险增加140%(HR=2.40,95%CI:1.27-4.52,P=0.007)。
- 敏感性分析结果相似。
关键数值与推荐
- 肌少症评估采用欧洲老年人肌少症工作组2标准。
临床怎么用
- 对老年炎症性肠病患者进行肌少症评估,有助于预后风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: With gradually increasing number of older patients with inflammatory bowel disease (IBD), a significant number of patients with IBD suffer from sarcopenia. Emerging evidence has demonstrated various adverse outcomes associated with sarcopenia; however, the impact of sarcopenia on long-term mortality risk among patients with IBD has not yet been explored. METHODS: Overall, 4,966 patients with IBD (aged 56.9 ± 8.0 years, 51.6% female) were enrolled in the prospective cohort. Sarcopenia was assessed according to criteria of the European Working Group on Sarcopenia in Older People 2. The primary outcome was all-cause mortality. Multivariable Cox proportional hazard model was conducted to estimate related associations. Sensitivity analysis and subgroup analysis were used to validate the results. RESULTS: Overall, 775 (14.6%) and 34 (0.7%) were considered probable sarcopenia and confirmed sarcopenia, respectively. During a median follow-up of 14.6 years, 564 all-cause deaths (11.4%) were identified. There were 136 deaths (17.5%) among those with probable sarcopenia and 10 deaths (29.4%) among those with confirmed sarcopenia. Compared with nonsarcopenia, those with probable sarcopenia and confirmed sarcopenia had a 47% (hazard ratio = 1.47, 95% confidence interval: 1.20-1.80, P < 0.001) and 140% (hazard ratio = 2.40, 95% confidence interval: 1.27-4.52, P = 0.007) excess risk of mortality, respectively. Similar results were observed in sensitivity analysis. DISCUSSION: Probable and confirmed sarcopenia increase the risk of long-term mortality in patients with IBD. Sarcopenia assessment can help risk stratification for prognosis in older patients with IBD.
引用
- Zhang Q, Liu H, Liu S, et al. Increased Mortality Associated With Sarcopenia in Inflammatory Bowel Disease: A Long-Term Prospective Cohort Study. Am J Gastroenterol. 2025. PMID: 40833430. doi:10.14309/ajg.0000000000003734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。